RxDoctor Payments Data

Alexandra Grace, DO

Gastroenterology · Naples, FLNPI 1861773533

Payments from drug & device makers

$10,723in general payments, 2019–2025

Across 429 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$924
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$902
  • Takeda Pharmaceuticals U.S.A., Inc.$875
  • Gilead$671
  • Boston Scientific$633
  • plus $4K from 30 others

What the payments were for

  • Food & beverage$10,52998%
  • Education$1942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,723 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$633,042
Medicare patients
1,617
Services billed
5,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$650,814
CreonLipase/Protease/Amylase91$272,228
ZeposiaOzanimod Hydrochloride28$254,595
ZenpepLipase/Protease/Amylase27$165,152
XifaxanRifaximin21$56,074
LinzessLinaclotide46$44,654
Dexlansoprazole DrDexlansoprazole66$23,096
MotegrityPrucalopride Succinate13$12,791
Mesalamine26$11,726
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C64$9,122
Pantoprazole Sodium374$6,128
Budesonide EcBudesonide13$5,752
Lubiprostone22$4,379
Omeprazole271$2,911
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$924$650,81424 claims
AbbVieCreon, Linzess$2,938$316,882137 claims
E.r. Squibb & Sons, L.L.C.Zeposia$20$254,59528 claims
Aimmune Therapeutics, Inc.Zenpep$206$165,15227 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$902$65,19685 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$875$12,79113 claims
Braintree Laboratories, Inc.Sutab$55$2,73817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →